High-intensity Focused Ultrasound for Prostate Cancer: A Systematic Review

Clinical Oncology

Volumn 23, Issue 2, 2011, Pages 117-127

  Lukka, H ^a   Waldron, T ^b   Chin, J ^c   Mayhew, L ^b   Warde, P ^d   Winquist, E ^c   Rodrigues, G ^c   Shayegan, B ^e  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

High intensity focused; Prostatic neoplasms; Systematic review; Transrectal; Ultrasound

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; EMBASE; EVIDENCE BASED PRACTICE CENTER; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MALE; MEDICAL RECORD REVIEW; MEDLINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

BRACHYTHERAPY; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; SALVAGE THERAPY; TREATMENT OUTCOME; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 79251609445     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.09.002     Document Type: Article

References (64)

1. National Cancer Institute of Canada Canadian cancer statistics 2009 2009, National Cancer Institute of Canada, Toronto.
2. Cooperberg M., Broering J., Litwin M., et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 2004, 171:1393-1401.
3. Partin A., Kattan M., Subong E., et al. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997, 277:118.
4. D'Amico A., Whittington R., Malkowicz S., et al. Pretreatment nanogram for prostate specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999, 17:168-172.
5. Lukka H., Warde P., Pickles T., et al. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol 2001, 8:1314-1322.
6. Hanks G., Hanlon A., Schultheiss T., Corn B., Shipley W., Lee W. Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies, with prospects for improvement with conformal radiation and adjuvant androgen deprivation. J Urol 1994, 152:1775-1780.
7. Pilepich M., Bagshaw M., Asbell S., et al. Definitive radiotherapy in resectable (stage A2 and B) carcinoma of the prostate-results of a nationwide overview. Int J Radiat Oncol Biol Phys 1987, 13:659-663.
8. Vallancien G., Prapotnich D., Cathelineau X., Baumert H., Rozet F. Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 2004, 171:2265-2267.
9. Rebillard X., Soulié M., Chartier-Kastler E., Davin J.-L., Mignard J.-P., Coulange C. High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int 2008, 101:1205-1213.
10. Tsakiris P., Thüroff S., De La Rosette J., Chaussy C. Transrectal high-intensity focused ultrasound devices: a critical appraisal of the available evidence. J Endourol 2008, 22:221-229.
11. National Collaborating Centre for Cancer CG58 Prostate cancer: evidence review. Available at http://www.nice.org.uk/nicemedia/pdf/CG58EvidenceReview.
12. Aus G. Current status of HIFU and cryotherapy in prostate cancer - a review. Eur Urol 2006, 50:927-934.
13. Hummel S., Paisley S., Morgan A., Currie E., Brewer N. Clinical and cost-effectiveness of new and emerging technologies for early localized prostate cancer: a systematic review. Health Technol Assess 2003, 7:1-157.
14. National Institute for Health and Clinical Excellence Interventional procedures overview of high-intensity focused ultrasound for prostate cancer 2004, Available at:. http://www.nice.org.uk/pdf/ip/IP230overview.
15. Pickles T., Goldenberg S.L., Steinhoff G. Technology review: high-intensity focused ultrasound for prostate cancer. Can J Urol 2005, 12:2593-2597.
16. National Institute for Health and Clinical Excellence High-intensity focused ultrasound for prostate cancer 2005, Available at:. http://www.nice.org.uk/pdf/ip/IPG118guidance.
17. National Collaborating Centre for Cancer Prostate cancer: diagnosis and treatment Available at. http://www.nice.org.uk/nicemedia/pdf/CG58NICEGuideline.
18. Chaussy C., Thüroff S. High-intensive focused ultrasound in localized prostate cancer. J Endourol 2000, 14:293-299.
19. Chaussy C., Thüroff S. Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J Endourol 2001, 15:437-440.
20. Thüroff S., Chaussy C., Vallancien G., et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 2003, 2003:673-677.
21. Chaussy C., Thüroff S. The status of high-intensity focused in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 2003, 4:248-252.
22. Thüroff S., Chaussy C. Efficacy of local high intensity focused ultrasound (HIFU) in localized prostate cancer. J Urol 2005, 173:279. [abstract].
23. Thüroff S., Knauer K., Chaussy C. Ten years high-intensity focused ultrasound (HIFU) as local treatment of prostate cancer: profile of side effects. Eur Urol 2006, 5:132. [abstract].
24. Chaussy C., Thüroff S., Knauer K. Ten years application of high-intensity focused ultrasound (HIFU) in prostate cancer (PCA). Eur Urol Suppl 2006, 5:133. [abstract].
25. Gelet A., Chapelon J., Bouvier R., Rouvière O., Lyonnet D., Dubernard J. Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol 2000, 14:519-528.
26. Gelet A., Chapelon J., Bouvier R., Rouvière O., Lyonnet D., Dubernard J. Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol 2001, 40:124-129.
27. Poissonnier L., Chapelon J.-Y., Rouvière O., et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007, 51:381-387.
28. Gelet A., Chapelon J.Y., Murat F.J., et al. Prostate cancer control with transrectal HIFU in 124 patients: 7-years' actuarial results. Eur Urol Suppl 2006, 5:133. [abstract].
29. Blana A., Walter B., Rogenhofer S., Wieland W.F. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004, 63:297-300.
30. Blana A., Rogenhofer S., Ganzer R., et al. Eight years; experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology 2008, 72:1329-1333.
31. Blana A., Rogenhofer S., Ganzer R., Wild P., Wieland W., Walter B. Morbidity associated with repeated transrectal high-intensity focused ultrasound of localized prostate cancer. World J Urol 2006, 24:535-590.
32. Blana A., Thüroff S., Murat F.-J., Walter B., Chaussy C., Gelet A. Long-term results with high intensity focused ultrasound (HIFU) in 140 patients with localized prostate cancer. Eur Urol Suppl 2007, 6:199. [abstract].
33. Blana A., Murat F.J., Walter B., et al. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 2008, 53(6):1194-1201.
34. Beerlage H.P., Thüroff S., Debruyne F.M.J., Chaussy C., de la Rosette J.J. Transrectal high-intensity focused ultrasound using the Ablatherm device in the treatment of localized prostate carcinoma. Urology 1999, 54:273-277.
35. Lee H., Hong J., Choi H. High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 2006, 9:439-443.
36. Mallick S., Dufour A., Fouques Y., Bensadoun H. High intensity focused ultrasound for the treatment of localized prostate cancer: are its efficacy and morbidity dogmatic [abstract] Available at:. http://www.abstracts2view.com/aua_archive/view.php%3Fnu%3D200691912.
37. Zizzi V., Piccinni R., Cafarelli A., Sblendorio D., Berardi B., Tempesta A. High-intensity focused ultrasound (HIFU) in prostate cancer [abstract]. Eur Urol Suppl 2006, 5:133.
38. Ganzer R., Rogenhofer S., Walter B., et al. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localized prostate cancer. Eur Urol 2008, 53:547-553.
39. Conort P.C., Rischmann P.R., Bensadoun H., et al. Treatment of localised prostate cancer by high intensity focused ultrasound (HIFU); results of the first French prospective study on patients not previously treated; minimum of five years follow-up. Eur Urol Suppl 2008, 7:119. [abstract].
40. Murat F.-J., Poissonnier L., Pricaz E., et al. Residual prostate cancer after a first HIFU session: oncological benefits of a second session [abstract] Available at:. http://www.uroweb.org/publications/eau-abstracts-online//%3FAID%3D18967.
41. Uchida T., Baba S., Irie A., et al. Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer: a multicenter study. Hinyokika Kiyo 2005, 51:651-658.
42. Uchida T., Ohkusa H., Nagata Y., Hyodo T., Satoh T., Irie A. Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 2006, 97:56-61.
43. Uchida T., Ohkusa H., Yamashita H., et al. Five years experience of transrectal high-intensity focused ultrasound using the Sonoblate device in the treatment of localized prostate cancer. Int J Urol 2006, 13:228-233.
44. Uchida T., Illing R.O., Cathcart P.J., Emberton M. The effect of neoadjuvant androgen suppression on prostate cancer-related outcomes after high-intensity focused ultrasound therapy. BJU Int 2006, 98:770-772.
45. Uchida T., Illing R.O., Cathcart P.J., Emberton M. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate?. BJU Int 2006, 98:537-539.
46. Mearini L., D'urso L., Collura D., et al. Transrectal high-intensity focused ultrasound (HIFU) using the sonoblate®500 for the treatment of prostate cancer; the Perugia-Torino experience. Eur Urol Suppl 2008, 7:120. [abstract].
47. Mearini L., D'Urso L., Collura D., et al. Visually directed transrectal high intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience. J Urol 2009, 181:105-111.
48. Muto S., Yoshii T., Saito K., Kamiyama Y., Ide H., Horie S. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 2008, 38:192-199.
49. Misraï V., Rouprêt M., Chartier-Kastler E., et al. Oncologic control provided by HIFU therapy as single treatment in men with clinically localized prostate cancer. World J Urol 2008, 26:481-485.
50. Thüroff S., Chaussy C. High-intensity focused ultrasound: complications and adverse events. Mol Urol 2000, 4:183-187.
51. Chaussy C., Thüroff S. High-intensity focused ultrasound in prostate cancer: results after 3 years. Mol Urol 2000, 4:179-182.
52. Thüroff S., Knauer K., Chaussy C. 10 years high intensity focused ultrasound (HIFU) as local treatment of prostate cancer: profile of side effects [abstract] Available at:. http://www.abstracts2view.com/aua_archive/view.php%3Fnu%3D200794031.
53. Thüroff S., Kiel H.J., Knauer K., Buehrend H., Chaussy C. High-intensity focused ultrasound (HIFU) in prostate cancer - side effects after 1000 treatments in 8 years. Eur Urol Suppl 2005, 4:82. [abstract].
54. Chaussy C., Thüroff S. Side effects of transrectal high intensity focused ultrasound (HIFU) in the local treatment of prostate cancer in 8 years [abstract] Available at:. http://www.abstracts2view.com/aua_archive/view.php%3Fnu%3D20054055.
55. Poissonnier L., Gelet A., Chapelon J.Y., et al. Prostate cancer control with transrectal HIFU in 230 patients: five-year results. Eur Urol Suppl 2005, 4:44. [abstract].
56. Gelet A., Chapelon J.Y., Poissonnier L., et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004, 63:625-629.
57. Poissonnier L., Gelet A., Chapelon J.-Y., et al. Local recurrence of prostate cancer after external beam radiation: early experience of salvage therapy using high intensity focused ultrasound. Eur Urol Suppl 2005, 7:79. [abstract].
58. Mallick S., Dufour A., Fouques Y., Bensadoun H. Salvage therapy using high-intensity focused ultrasound for local recurrence of prostate cancer after radiation therapy. Eur Urol Suppl 2006, 5:132. [abstract].
59. Murat F.-J., Chapelon J.Y., Poissonnier L., et al. Salvage HIFU for radiorecurrent prostate cancer: factors influencing the outcome. Eur Urol Suppl 2006, 5:133. [abstract].
60. Murat F.-J., Poissonnier L., Rouvière O., et al. Salvage high intensity focused ultrasound (HIFU) treatment for recurrent prostate cancer after radiation therapy: high efficacy in patients with good initial prognosis [abstract] Available at:. http://www.abstracts2view.com/aua_archive/view.php%3Fnu%3D200794031.
61. Murat F.-J., Poissonnier L., Pricaz E., et al. Prognostic factors for salvage HIFU success after external beam radiation failure (EBRT) failure. Eur Urol Suppl 2008, 7:119. [abstract].
62. Murat F.J., Poissonnier L., Rouvière O., et al. High efficacy of salvage HIFU treatment for radiorecurrent prostate cancer in patient with good initial prognosis. J Urol 2007, 6:200. [abstract].
63. Murat F.J., Poissonnier L., Rabilloud M., et al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol 2009, 55:640-649.
64. National Institute for Health and Clinical Excellence High-intensity focused ultrasound for prostate cancer 2005, Available at:. http://guidance.nice.org.uk/IPG118.